These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22484547)

  • 1. Strategic alliances and market risk.
    Havenaar M; Hiscocks P
    Drug Discov Today; 2012 Aug; 17(15-16):824-7. PubMed ID: 22484547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovation in biotechnology: moving from academic research to product development--the case of biosensors.
    Siontorou CG; Batzias FA
    Crit Rev Biotechnol; 2010 Jun; 30(2):79-98. PubMed ID: 20214418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Licensing: pros and cons for biotech.
    Villiger R; Bogdan B
    Drug Discov Today; 2009 Mar; 14(5-6):227-30. PubMed ID: 19200456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model of strategic marketing alliances for hospices: vertical, internal, osmotic alliances and the complete model.
    Starnes BJ; Self DR
    J Hosp Mark; 1999; 13(1):43-56. PubMed ID: 10623195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery alliances in India--indications, targets, and new chemical entities.
    Differding E
    ChemMedChem; 2014 Jan; 9(1):43-60. PubMed ID: 24136820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca.
    Janero DR
    Expert Opin Drug Discov; 2012 Jun; 7(6):449-56. PubMed ID: 22540843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic alliances in health care: the challenges of cooperation.
    Zuckerman HS; Kaluzny AD
    Front Health Serv Manage; 1991; 7(3):3-23, 35. PubMed ID: 10109087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategic considerations for the biotechnology business to the year 2000.
    Cometta S
    Arzneimittelforschung; 1989 Aug; 39(8):929-34. PubMed ID: 2818683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical new product development: the increasing role of in-licensing.
    Edwards NV
    Anesthesiol Clin; 2008 Dec; 26(4):627-36, v. PubMed ID: 19041620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When more isn't merrier: pharmaceutical alliance networks and breakthrough innovation.
    Dong JQ; McCarthy KJ
    Drug Discov Today; 2019 Mar; 24(3):673-677. PubMed ID: 30639556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 16. Overcoming further challenges in the pharma/biotech industry: 2007 update.
    Graul AI; Cruces E; Revel L; Serradell N; Rosa E
    Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When to ally & when to acquire.
    Dyer JH; Kale P; Singh H
    Harv Bus Rev; 2004; 82(7-8):108-15, 188. PubMed ID: 15241957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-licensing as a business model.
    Schafer DP
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE36-9. PubMed ID: 12089585
    [No Abstract]   [Full Text] [Related]  

  • 19. Taking the pulse of strategic outsourcing relationships.
    Getz KA; Lamberti MJ; Kaitin KI
    Clin Ther; 2014 Oct; 36(10):1349-55. PubMed ID: 25444564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.